本院通過 ISO 9001:2008 全院認證、ISO 15189 醫學實驗室認證;榮獲 SNQ 國家品質標章 網站導覽 相關連結 聯絡我們(另開新視窗) 回首頁 回胸腔病首頁

這個頁面上的內容需要較新版本的 Adobe Flash Player。

取得 Adobe Flash Player

醫院的形像圖示切換動畫
:::
捷徑位置: 首頁 >> MDR-TB專區 >> 衛教宣導
MDR-TB專區
 
主題 :   [TB news]TB Immunotherapy Collaboration Agreement With Stirling Products and Zod
內容 :  
    資料來源:生策會

    Globenewswire

     VANCOUVER, British Columbia, May 30, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that it has entered into a conditional agreement with Australian-based Stirling Products Limited (ASX:STI) and Zodiac Capital Limited (NSX:ZOD) (the Australian partners) with regard to an improved formulation of Immunoxel/Dzherelo recently developed and clinically tested by the Company.

     The new sublingual tablet formulation has already demonstrated potential for improved effectiveness. Importantly, the decreased cost of production, improved stability and ease of use of the new Immunoxel/Dzherelo formulation is likely to improve the accessibility and availability of the product for TB patients.

     Under the terms of the Agreement, the Company and its Australian partners will continue with their respective R&D work. Stirling Products will continue with its plans for a Co-operative Research Agreement with the US National Institutes of Health (NIH) while the Company will produce batches of the new product and continue clinical demonstration trials. The Agreement is conditional upon the Company becoming current in its statutory filings, following which the Company will issue 20 million shares to its Australian partners for the non-exclusive marketing rights to ImmunoXel. Further, the Company's Australian partners will subscribe to 5 million Immune shares at US$0.02 per share with such subscription to be satisfied by the issue of shares in the Australian partner public companies Stirling Products and Zodiac Capital at current market prices.

     Immunoxel/Dzherelo is a multi-herbal extract product that has been shown in a dozen clinical trials, published in peer-reviewed journals, to be surprisingly effective as an adjuvant immunotherapy in treatment of TB patients, including patients with multi-drug resistant (MDR-TB) and extensively drug resistant TB (XDR-TB), and TB patients who are co-infected with HIV. The new sub-lingual lozenge formulation is optimized for potency, stability, low cost, and patient compliance. Positive clinical data for Dzherelo lozenges has been presented at two conferences so far this year: clinical evidence suggests approximately 90% of patients supplementing standard TB treatment with such sublingual tablets are cured (sputum clearance of TB) within one month.

     The World Health Organisation (WHO) estimates that globally, about one-third of the world's population is infected with the Mycobacterium tuberculosis bacteria that cause TB, and each year approximately 9 million people become ill with the disease and 2 million die from it. TB patients with HIV are 30 times more likely to die and treatment options for them are limited. A 2009 WHO annual report on TB indicated that one in four TB deaths is HIV-related, twice as many as had been recognized previously. In addition about half a million people had MDR-TB in 2007. But due to lack of adequate treatment, which can be costly and complicated, only about 1 percent of such individuals are treated. The introduction of immunotherapy interventions such as Immunoxel/Dzherelo has the potential to reverse the crisis situation in current TB management, especially with respect to MDR-TB and XDR-TB.

    ***行政院衛生署胸腔病院關心您!***
 

回上一頁 | 友善列印

:::網站資訊
4541730
網路分享
快速選單
更多影片詳細資料
快速連結
網路掛號
團隊介紹
結核病診治指引
相關連結
連結以病友為中心的多重抗藥性結核病醫療照護(另開視窗)
 
連結WHO | World Health Organization(另開視窗)
 
連結Stop TB Partnership(另開視窗)
 
連結International Union Against Tuberculosis and Lung Disease(另開視窗)
 
連結American Thoracic Society(另開視窗)
 
連結防癆協會(另開視窗)
 
連結結核病醫學會(另開視窗)
 
連結內科醫學會(另開視窗)
 
連結胸腔暨重症加護醫學會(另開視窗)
 
連結感染症醫學會(另開視窗)
 
連結台灣醫學院感染控制學會(另開視窗)
 
連結家庭醫學會(另開視窗)
 
連結ADR全國藥物不良反應通報系統(另開視窗)
 
連結TDRF財團法人藥害救濟基金會(另開視窗)
 
連結綠色環保資訊(另開視窗)
 
連結檳榔一口口 健康就失守(另開視窗)
 
連結自殺防治中心(另開視窗)
 
連結節能減碳全民行動網(另開視窗)
 
連結行政院原子能委員會環境輻射監測(另開視窗)
 
回首頁 | 本院位置 | 無障礙宣告 | 隱私權政策 | 網站安全政策 | 資訊安全政策
 衛生福利部胸腔病院 
 電話: 院本部/06-2705911(總機) 門診部/06-2146006(總機)  傳真: 院本部/06-2703400 
 地址: 院本部/71742台南市仁德區中山路864號 門診部/70141台南市東區大同路一段69號 
 預掛專線:06-2142619(人工) 
本網站已通過A+等級無障礙網頁檢測